Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases Patient Guide in Prostate Cancer Now Available Also in German MOST POPULAR An existing blood test for ovarian cancer has been re-evaluated. The... October 28, 2020 Answers to Your Questions About Sunscreen Ingredients April 21, 2022 EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment... October 21, 2021 Advancing Cancer Research as a Married Couple: “Your Stories” Podcast December 18, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March
